Shield Therapeutics plc (STX.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
Northern Design Centre
Gateshead, GH NE8 3DF
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1915 118 500
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
61
First IPO Date
February 26, 2016
| Name | Title | Pay | Year Born |
| Anders Lundstrom | CEO, Interim CFO & Director | 439,865 | 1962 |
| Christian Schweiger | Co-Founder & Non Executive Director | 96,174 | 1966 |
| Kate Armanetti | Senior Director of People & Culture | 0 | N/A |
| Andrew Hurley | Chief Commercial Officer | 0 | 1969 |
| David Childs | Senior VP of Manufacturing & Strategic Alliances | 0 | N/A |
| Santosh Shanbhag | Chief Financial Officer | 0 | 1978 |
| Carol Akinola | Head of Pharmacovigilance & Medical Information | 0 | N/A |
| Lucy Kate Huntington-Bailey | General Counsel, Chief Compliance Officer & Company Secretary | 0 | N/A |
| Suzanne Wood | Group HR Director | 0 | N/A |
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.